Four medical research organizations sign deals to do work on Vast’s space stations
Capitalism in space: The space station startup up Vast yesterday announced that three medical research companies and one university institute have signed preliminary agreements to continue and expand their ISS biological research on Vast’s Haven-1 and Haven-2 space stations.
Vast, the company building next-generation space stations and space infrastructure, announced today memorandums of understanding (MoUs) with UC San Diego’s Sanford Stem Cell Institute, Auxilium Biotechnologies, LambdaVision, and BioOrbit, advancing its network of microgravity research and manufacturing partners. Vast’s network brings together world-class universities, pioneering researchers, and cutting-edge technology providers to shape the future of microgravity research and manufacturing conducted in low-Earth orbit (LEO).
Though all four have done pure research on ISS, none have been permitted to produce products there for sale on Earth, due to NASA’s anti-commercial regulations. This will change on the new private stations. For example, LambdaVision has already signed an earlier agreement with the Starlab station to use it to manufacture its artificial retinas for sale. Auxilium meanwhile has already demonstrated on ISS the ability to create implantable medical devices using 3D printing. On Vast’s stations it will be able to expand this work by producing saleable products. BioOrbit in turn will use the Haven stations to begin manufacturing the zero gravity pharmaceuticals it has already tested on ISS.
Below is my updated ranking of the five American space stations presently under development:
» Read more



